Insmed Incorporated
(NASDAQ : INSM)

( )
INSM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.26%87.921.3%$848.13m
BIIBBiogen Inc.
1.64%220.261.3%$580.78m
AMGNAmgen Inc.
-0.06%186.591.2%$533.06m
ONCESpark Therapeutics, Inc.
0.47%113.5311.2%$497.94m
GILDGilead Sciences, Inc.
0.03%63.790.9%$468.70m
REGNRegeneron Pharmaceuticals, Inc.
0.82%395.002.6%$283.62m
ILMNIllumina, Inc.
-1.65%303.713.5%$275.40m
VRTXVertex Pharmaceuticals Incorporated
1.28%183.851.9%$247.78m
SRPTSarepta Therapeutics, Inc.
-2.73%118.9215.4%$216.64m
BPTHBio-Path Holdings, Inc.
-12.42%19.25190.1%$203.41m
ALXNAlexion Pharmaceuticals, Inc.
1.60%132.292.0%$187.73m
EXASExact Sciences Corporation
0.07%89.0625.3%$173.12m
AAgilent Technologies, Inc.
0.66%79.511.6%$122.76m
IONSIonis Pharmaceuticals, Inc.
0.18%79.048.3%$109.28m
INCYIncyte Corporation
0.80%86.022.5%$93.70m

Company Profile

Insmed, Inc. operates as a biopharmaceutical company. It focus developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. The firm develops and commercialization of ARIKAYCE or liposomal amikacin for inhalation for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded in 1988 and is headquartered in Bridgewater, NJ.